NWBO vs. ARDX
NWBO (Northwest Biotherapeutics, Inc.) and ARDX (Ardelyx, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, NWBO returned -11.32%/yr vs -2.60%/yr for ARDX. At a 0.11 correlation, their price movements are largely independent.
Performance
NWBO vs. ARDX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NWBO achieves a -16.85% return, which is significantly lower than ARDX's 6.00% return. Over the past 10 years, NWBO has underperformed ARDX with an annualized return of -11.32%, while ARDX has yielded a comparatively higher -2.60% annualized return.
NWBO
- 1D
- -0.83%
- 1M
- -18.51%
- YTD
- -16.85%
- 6M
- -23.86%
- 1Y
- -26.28%
- 3Y*
- -31.62%
- 5Y*
- -33.92%
- 10Y*
- -11.32%
ARDX
- 1D
- -2.98%
- 1M
- 1.15%
- YTD
- 6.00%
- 6M
- 6.55%
- 1Y
- 70.25%
- 3Y*
- 19.74%
- 5Y*
- -4.70%
- 10Y*
- -2.60%
NWBO vs. ARDX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NWBO Northwest Biotherapeutics, Inc. | -16.85% | -16.74% | -60.81% | -10.64% | 12.07% | -54.10% | 626.19% | 2.19% | -14.38% | -31.05% |
ARDX Ardelyx, Inc. | 6.00% | 14.99% | -18.23% | 117.54% | 159.09% | -83.00% | -13.79% | 319.27% | -72.88% | -53.52% |
Correlation
The correlation between NWBO and ARDX is -0.03, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.03 |
Correlation (3Y) Calculated over the trailing 3-year period | -0.02 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.05 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.07 |
Correlation (All Time) Calculated using the full available price history since Jun 19, 2014 | 0.11 |
The correlation between NWBO and ARDX shifts across timeframes, from -0.03 (1 year) to 0.11 (all time), reflecting how their relationship changes across market environments.
Fundamentals
NWBO:
-$0.06
ARDX:
-$0.24
NWBO:
297.41
ARDX:
3.51
NWBO:
$937.00K
ARDX:
$427.68M
NWBO:
$416.00K
ARDX:
$395.63M
NWBO:
-$79.62M
ARDX:
-$28.55M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NWBO vs. ARDX — Risk / Return Rank
NWBO
ARDX
NWBO vs. ARDX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Northwest Biotherapeutics, Inc. (NWBO) and Ardelyx, Inc. (ARDX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NWBO | ARDX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.54 | ||
| Sortino ratioReturn per unit of downside risk | -2.34 | ||
| Omega ratioGain probability vs. loss probability | 0.98 | 1.26 | -0.28 |
| Calmar ratioReturn relative to maximum drawdown | -0.63 | 2.11 | -2.74 |
| Martin ratioReturn relative to average drawdown | -1.12 | 4.07 | -5.19 |
Loading charts...
Drawdowns
NWBO vs. ARDX - Drawdown Comparison
The maximum NWBO drawdown since its inception was -99.99%, roughly equal to the maximum ARDX drawdown of -98.45%. Use the drawdown chart below to compare losses from any high point for NWBO and ARDX.
Loading charts...
Drawdown Indicators
| NWBO | ARDX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.99% | -98.45% | -1.54% |
Max Drawdown (1Y)Largest decline over 1 year | -41.54% | -33.54% | -8.00% |
Max Drawdown (3Y)Largest decline over 3 years | -82.16% | -66.32% | -15.84% |
Max Drawdown (5Y)Largest decline over 5 years | -90.29% | -93.76% | +3.47% |
Max Drawdown (10Y)Largest decline over 10 years | -91.93% | -96.82% | +4.89% |
Current DrawdownCurrent decline from peak | -99.99% | -81.21% | -18.78% |
Average DrawdownAverage peak-to-trough decline | -97.15% | -77.37% | -19.78% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 23.56% | 17.31% | +6.25% |
Volatility
NWBO vs. ARDX - Volatility Comparison
Northwest Biotherapeutics, Inc. (NWBO) has a higher volatility of 17.80% compared to Ardelyx, Inc. (ARDX) at 12.95%. This indicates that NWBO's price experiences larger fluctuations and is considered to be riskier than ARDX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NWBO | ARDX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.80% | 12.95% | +4.85% |
Volatility (6M)Calculated over the trailing 6-month period | 47.20% | 46.39% | +0.81% |
Volatility (1Y)Calculated over the trailing 1-year period | 67.36% | 61.42% | +5.94% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 81.98% | 89.49% | -7.51% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 92.88% | 83.99% | +8.89% |
Dividends
NWBO vs. ARDX - Dividend Comparison
Neither NWBO nor ARDX has paid dividends to shareholders.
Financials
NWBO vs. ARDX - Financials Comparison
This section allows you to compare key financial metrics between Northwest Biotherapeutics, Inc. and Ardelyx, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
NWBO and ARDX have a correlation of -0.03, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NWBO has higher volatility (17.80%) compared to ARDX (12.95%). In terms of maximum drawdown, NWBO dropped -99.99% vs ARDX's -98.45%.
ARDX currently has the higher Sharpe Ratio (1.15 vs -0.39), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NWBO and ARDX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer